Nevanac (Nepafenac) Patent Expiration, LOE Window & CMS Spending
Nevanac (Nepafenac) by Harrow Eye: FDA Orange Book LOE 2027-01-31, 0 AB generics, $1.9M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Harrow Eye |
| FDA Application & Pathway | N021862 (NDA) |
| Exclusivity / Cliff Horizon | Immediate Cliff (2025-2027) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2027-01-31 |
| Orange Book Patents (*PED Extensions) | 1 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $1.9M |
| 2024 Medicare Part D Spend | $1.7M |
| 2024 Medicaid Spend | $153K |
| Reported Wholesale Price Change (CA SB 17) | 1 WAC filings (max 21.2% 2-yr change) |